ID: ALA5280702

Max Phase: Preclinical

Molecular Formula: C18H24N2O

Molecular Weight: 284.40

Associated Items:

Representations

Canonical SMILES:  CN1CCN(CCCOc2ccc3ccccc3c2)CC1

Standard InChI:  InChI=1S/C18H24N2O/c1-19-10-12-20(13-11-19)9-4-14-21-18-8-7-16-5-2-3-6-17(16)15-18/h2-3,5-8,15H,4,9-14H2,1H3

Standard InChI Key:  QXTADKACYIMHII-UHFFFAOYSA-N

Associated Targets(Human)

HRH3 Tclin Histamine H3 receptor (10389 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

ache Acetylcholinesterase (12221 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BCHE Cholinesterase (8742 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 284.40Molecular Weight (Monoisotopic): 284.1889AlogP: 2.86#Rotatable Bonds: 5
Polar Surface Area: 15.71Molecular Species: NEUTRALHBA: 3HBD: 0
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.11CX LogP: 2.73CX LogD: 1.94
Aromatic Rings: 2Heavy Atoms: 21QED Weighted: 0.79Np Likeness Score: -1.11

References

1. Aranha CMSQ, Reiner-Link D, Leitzbach LR, Lopes FB, Stark H, Fernandes JPS..  (2023)  Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H3 and dopamine D3 receptors.,  78  [PMID:36542960] [10.1016/j.bmc.2022.117132]

Source